Founded in San Diego, California, Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for individuals living with rare diseases. The company's core mission is to provide innovative treatments that address unmet medical needs globally. Among its notable products is FILSPARI® (sparsentan), which has received accelerated approval for treating IgA nephropathy in adults.
Travere Therapeutics has garnered support from prominent investors and industry experts, contributing to its significant achievements in the rare disease sector. The company's impact is evident through its global reach and the positive outcomes experienced by patients using its therapies. By focusing on rare diseases, Travere Therapeutics continues to make substantial strides in improving the quality of life for those affected by these conditions.
